Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks

@article{Turner2007ClinicalIO,
  title={Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks},
  author={Michelle S. Turner and D. Byron May and Ray R. Arthur and Glen L. Xiong},
  journal={Journal of Internal Medicine},
  year={2007},
  volume={261}
}
The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti‐inflammatory… Expand
Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding
TLDR
The purpose of this article is to review the incidence of gastrointestinal tract bleeding or intracranial bleeding associated with concomitant SSRI use, the proposed mechanisms of, and the potential pharmacokinetic/pharmacodynamic interactions with anticoagulants and antiplatelets. Expand
[SSRI - treatment and bleeding. What risks do we take?].
TLDR
High-risk patients have to be followed up closely and an SSRI with a low potential for drug interaction should be used and the prescription of gastroprotective agents and a change of the antidepressant should be considered in particular cases. Expand
Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
Although the selective serotonin reuptake inhibitors (SSRIs), which are now widely used as a first-line treatment for depression and many other psychiatric conditions, are generally well tolerated,Expand
Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.
TLDR
Antidepressants with a relevant blockade action on the serotonin reuptake mechanism increase the risk of upper gastrointestinal tract bleeding, and evidence that use of acid-suppressing agents limits such increased risk is provided. Expand
Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer
TLDR
The results do not support the serotonin-mediated pathway for the prolactin-breast cancer hypothesis, and there is no conclusive evidence of breast cancer risk associated with the use of SSRIs even after assessing the degree of serotonin reuptake inhibition and duration of use. Expand
Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors
TLDR
Comparisons between patients who were treated with low-molecular-weight heparin for venous thromboembolism on SSRIs and those not on chronic SSRI therapy found no difference, but ad hoc findings showed a significantly higher rate of major bleeding events in patients who received escitalopram and alcohol among patients on full-dose enoxaparin for VTE. Expand
Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta‐analysis of observational studies
TLDR
This meta‐analysis shows an increased risk of bleeding of at least 36% (from 12% to 64%) based on the high‐level of observational studies with SSRIs use, which is consistent whatever the characteristics of studies. Expand
Abnormal bleeding after an oral surgical procedure leading to airway compromise in a patient taking a selective serotonin reuptake inhibitor and a nonsteroidal antiinflammatory drug.
TLDR
A case of abnormal bleeding after an oral surgical procedure leading to airway compromise in a patient taking a selective serotonin reuptake inhibitor and a nonsteroidal antiinflammatory drug is reported. Expand
Drugs that affect platelet function.
  • R. Scharf
  • Medicine
  • Seminars in thrombosis and hemostasis
  • 2012
TLDR
A review of the large variety of agents that have not been designed for antiplatelet therapy but nevertheless interfere with platelet reactivity or induce platelet inhibition is provided. Expand
A study of the increased risk of bleeding events in patients with blood clotting disorders, associated with antidepressant medication use
TLDR
The use of SSRI and SNRI antidepressant medications was not associated with an increased risk of bleeding events in this study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
TLDR
Independently of the brand, use of SSRIs is indeed associated with increased bleeding risk, and physicians should be aware of SSRI-induced hemorrhages, especially in patients with hereditary platelet defects, and those treated with antiplatelet agents. Expand
Selective serotonin reuptake inhibitors: infrequent medical adverse effects.
TLDR
5 relatively infrequent adverse medical effects associated with the use of selective serotonin reuptake inhibitors are reviewed: the syndrome of inappropriate antidiuretic hormone secretion, extrapyramidal effects, bleeding complications, cardiac arrhythmias, and the serotonin syndrome. Expand
Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence.
TLDR
It is possible that the effects SSRI on platelet functioning are causing the bleeding observed in some patients and/or that a separate coagulopathy is present and contributing to bleeding. Expand
Does concurrent prescription of selective serotonin reuptake inhibitors and non‐steroidal anti‐inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?
TLDR
A 15‐fold increased risk of gastrointestinal bleeding has been reported with concurrent use of selective serotonin reuptake inhibitors and non‐steroidal anti‐inflammatory drugs, particularly in older people. Expand
Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.
TLDR
Selective serotonin reuptake inhibitors increase the risk of upper GI bleeding, and this effect is potentiated by concurrent use of nonsteroidal anti-inflammatory drugs or low-dose aspirin, whereas an increased risk ofupper GI bleeding could not be attributed to other types of antidepressants. Expand
Hypothesis: Antiplatelet Effects of Selective Serotonin Reuptake Inhibitors Cause Clinical Benefits on Cardiovascular Disease and Increase Risks of Bleeding
TLDR
The totality of evidence is limited but compatible with the hypothesis that SSRIs cause clinical benefits on occlusive cardiovascular disease and increase risks of bleeding. Expand
Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin
TLDR
In patients with CHF already on aspirin, SSRI therapy was associated with further inhibition of platelet function, and this observation may help to explain some of the clinical benefits associated with SSRIs. Expand
Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.
TLDR
The results are not compatible with a major increased risk of intracranial haemorrhage among users of SSRIs or other antidepressants at large, however, smaller but still relevant increased risks cannot be ruled out. Expand
Selective serotonin reuptake inhibitors. Pharmacology and clinical implications in anaesthesia and critical care medicine.
TLDR
The newer, selective serotonin reuptake inhibitors are increasingly used in psychiatry in both children and adults, and can cause significant physiological changes and drug interactions which have implications for the anaesthetist and the critical care physician, especially the potential to induce the serotonin syndrome. Expand
Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease.
TLDR
The present study compares the differences in platelets dependent on SSRI using a variety of techniques including conventional aggregometry in plasma and whole blood, expression of major surface receptors by flow cytometry, and quantitatively by platelet function analyzers. Expand
...
1
2
3
4
5
...